Header Logo

Connection

Lise Jamieson to Humans

Back to Details
This is a "connection" page, showing publications Lise Jamieson has written about Humans.
Lise Jamieson
Connection Strength
0,746
Humans
  1. How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from a retrospective cohort study in Zambia. BMJ Open. 2022 12 22; 12(12):e064070.
    View in: PubMed
    Score: 0,064
  2. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
    View in: PubMed
    Score: 0,063
  3. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
    View in: PubMed
    Score: 0,059
  4. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,057
  5. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
    View in: PubMed
    Score: 0,053
  6. Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa. BMC Public Health. 2019 Dec 05; 19(1):1638.
    View in: PubMed
    Score: 0,051
  7. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Med. 2017 09; 18(8):595-603.
    View in: PubMed
    Score: 0,043
  8. Integrated multi-month dispensing for HIV and hypertension in South Africa: A model of epidemiological impact and cost-effectiveness. J Int AIDS Soc. 2025 Feb; 28(2):e26413.
    View in: PubMed
    Score: 0,018
  9. Ten-year health impact, economic impact and return on investment of the South African molecular diagnostics programme for HIV, tuberculosis and SARS-CoV-2. BMJ Glob Health. 2024 Dec 03; 9(12).
    View in: PubMed
    Score: 0,018
  10. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme. Vaccine. 2024 Aug 13; 42(20):125988.
    View in: PubMed
    Score: 0,018
  11. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: a mathematical modelling study. Lancet Public Health. 2024 Apr; 9(4):e218-e230.
    View in: PubMed
    Score: 0,017
  12. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS. 2024 03 15; 38(4):589-594.
    View in: PubMed
    Score: 0,017
  13. A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study. BMC Public Health. 2023 10 27; 23(1):2119.
    View in: PubMed
    Score: 0,017
  14. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc. 2023 07; 26 Suppl 2:e26106.
    View in: PubMed
    Score: 0,016
  15. Attrition from HIV treatment after enrollment in a differentiated service delivery model: A cohort analysis of routine care in Zambia. PLoS One. 2023; 18(3):e0280748.
    View in: PubMed
    Score: 0,016
  16. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255.
    View in: PubMed
    Score: 0,016
  17. Assessment of facility-level antiretroviral treatment patient status utilizing a national-level laboratory cohort: Toward an understanding of system-level tracking and clinic switching in South Africa. Front Public Health. 2022; 10:959481.
    View in: PubMed
    Score: 0,016
  18. Developing and testing unconditional cash transfer strategies among young adults with first-episode psychosis in South Africa: a study protocol for a pilot randomised control trial (PRS-FEP trial). BMJ Open. 2022 12 05; 12(12):e067026.
    View in: PubMed
    Score: 0,016
  19. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.
    View in: PubMed
    Score: 0,016
  20. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
    View in: PubMed
    Score: 0,015
  21. Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan. 2021 Nov 11; 36(10):1545-1551.
    View in: PubMed
    Score: 0,015
  22. The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. Clin Infect Dis. 2021 05 04; 72(9):1642-1644.
    View in: PubMed
    Score: 0,014
  23. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
    View in: PubMed
    Score: 0,014
  24. Community-based delivery of HIV treatment in Zambia: costs and outcomes. AIDS. 2021 02 02; 35(2):299-306.
    View in: PubMed
    Score: 0,014
  25. Steep Declines in Pediatric AIDS Mortality in South Africa, Despite Poor Progress Toward Pediatric Diagnosis and Treatment Targets. Pediatr Infect Dis J. 2020 09; 39(9):843-848.
    View in: PubMed
    Score: 0,014
  26. The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case. PLoS One. 2019; 14(2):e0210497.
    View in: PubMed
    Score: 0,012
  27. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS One. 2018; 13(10):e0204020.
    View in: PubMed
    Score: 0,012
  28. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
    View in: PubMed
    Score: 0,012
  29. Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS One. 2018; 13(8):e0201955.
    View in: PubMed
    Score: 0,012
  30. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
    View in: PubMed
    Score: 0,011
  31. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 01 31; 17(1):143.
    View in: PubMed
    Score: 0,011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.